Clinical and Molecular Epidemiology of Multidrug-Resistant *P. aeruginosa* Carrying \(\text{aac}(6')-\text{Ib-cr}\), \(\text{qnrS}1\) and \(\text{bla}_{\text{SPM}}\) Genes in Brazil

Bruna Fuga Araujo\(^*\), Melina Lorraine Ferreira\(^1\), Paola Amaral de Campos\(^1\), Sabrina Royer\(^1\), Deivid William da Fonseca Batistão\(^1\), Raquel Cristina Cavalcanti Dantas\(^1\), Iara Rossi Gonçalves\(^1\), Ana Luiza Souza Faria\(^1\), Cristiane Silveira de Brito\(^1\), Jonny Yokosawa\(^2\), Paulo Pinto Gontijo-Filho\(^1\), Rosineide Marques Ribas\(^1\)

\(^1\) Instituto de Ciências Biomédicas (ICBIM), Laboratory of Molecular Microbiology, Universidade Federal de Uberlândia (UFU), Uberlândia, Minas Gerais, Brazil, \(^2\) Instituto de Ciências Biomédicas (ICBIM), Laboratory of Virology, Universidade Federal de Uberlândia (UFU), Uberlândia, Minas Gerais, Brazil

\* bruna.fuga@hotmail.com

Abstract

We described a comprehensive analysis of the molecular epidemiology of multidrug-resistant (MDR) *P. aeruginosa*. Molecular analysis included typing by Pulsed Field Gel Electrophoresis, identification of genes of interest through PCR-based assays and sequencing of target genes. Case-control study was conducted to better understand the prognostic of patients and the impact of inappropriate therapy in patients with bacteremia, as well as the risk factors of MDR infections. We observed a high rate of MDR isolates (40.7%), and 51.0% of them was independently associated with inappropriate antibiotic therapy. Bacteremia was detected in 66.9% of patients, and prolonged hospital stay was expressive in those resistant to fluoroquinolone. Plasmid-mediated quinolone resistance genes (PMQR), \(\text{qnrS}1\) and \(\text{aac}(6')-\text{Ib-cr}\), were detected in two different nosocomial isolates (5.3%), and the \(\text{aac}(6')-\text{Ib}-\text{b}1\) variant was detected at a high frequency (87.5%) in those negative to PMQR. The presence of mutations in \(\text{gyrA}\) and \(\text{parC}\) genes was observed in 100% and 85% of selected isolates, respectively. Isolates harboring PMQR genes or mutations in \(\text{gyrA}\) and \(\text{parC}\) were not closely related, except in those containing SPM (São Paulo metallo-β-lactamase) clone. In addition, there is no study published in Brazil to date reporting the presence of *Pseudomonas aeruginosa* isolates harboring both \(\text{qnrS}1\) and \(\text{aac}(6')-\text{Ib-cr}\) genes, with alarming frequency of patients with inappropriate therapy.

Introduction

Currently, the increasing incidence of MDR *P. aeruginosa* is a global problem as a consequence of the ability of this microorganism to develop resistance to almost all antibiotics.
that are available for treatment, either by mutations present in chromosomal gene, or by horizontal gene transfer [1,2]. In Brazil, this problem is aggravated because of either the very high density of the antimicrobials use, especially β-lactams (including carbapenems) and fluoroquinolones [3,4] and the lack of affirmative action’s for prevention of these infections [5,6].

Carbapenems are a therapeutic choice for the treatment of severe infections caused by *P. aeruginosa*. However, its use has been threatened mainly by the increased incidence of isolates resistant to this class of antibiotics [7–9]. Among the carbapenem resistance mechanisms, there is the presence of carbapenemases, which are a heterogeneous group of β-lactamases comprising Classes A (penicillinas), B (metalloenzymes) and D (oxacillinas), with the ability to hydrolyze imipenem and meropenem in addition to other penicillins and cephalosporins [10]. The genes encoding the carbapenemases are usually located in plasmids, which significantly increase the risk of their dissemination [11,12]. The carbapenem resistance in *P. aeruginosa* infection occurs mainly by metallo-β-lactamase (MBL), in addition to the appearance of other β-lactamases with carbapenemase activity, including KPC (*Klebsiella pneumoniae* carbapenemase) and OXA-carbapenemase [7,9,13,14].

In recent years, the production of MBL by *P. aeruginosa* isolates has assumed epidemiological importance and is associated with high mortality rates [15]. MBLs confer resistance to carbapenems, and are generally encoded by mobile elements facilitating the spread of antibiotic resistance [16–18]. The *bla*<sub>SPM-1</sub> gene has been spread in Brazilian regions by the persistent MDR *P. aeruginosa*, and studies have reported concerns about its worldwide spread and potential pandemic [7, 18–20]. The increased prevalence of infections and colonization by *P. aeruginosa* São Paulo metallo-β-lactamases (SPM)-producers suggests that the gene *bla*<sub>SPM-1</sub> settled successfully in plasmids and is associated with high risk of formation of clones, which can facilitate its global spread [21, 22].

Beyond the potent *in vitro* anti-pseudomonal activity, the use of fluoroquinolone antibiotics has spread widely in the past decade, and its usage popularity has also facilitated the emergence of resistant and MDR strains [23]. The resistance to fluoroquinolones is mainly due to (i) the point mutations in quinolone resistance determining regions (QRDR) in the DNA gyrase (*gyrA* and *gyrB*) and topoisomerase IV (*parC* and *parE*) genes, (ii) the presence of plasmid-mediated quinolone resistance (PMQR) determinants, and/or (iii) the decreased uptake of the drug due to the loss of a membrane-bound porin and/or drug extrusion via efflux pumps [24]. The co-existence of mutations in genes encoding for type-II topoisomerase and PMQR is often found together in microorganisms of the *Enterobacteriaceae* family, and the presence of PMQR determinants may promote QRDR mutations, increasing the resistance to fluoroquinoline [25, 26]. Although PMQR genes, such as *qnrA*, *qnrB*, *qnrC*, *qnrD*, *qnrS*, *qepA* and *aac(6')-Ib-cr*, have been increasingly reported in bacterial pathogens within the *Enterobacteriaceae* family, they have not been detected frequently in *P. aeruginosa* isolates [24, 27]. To the best of our knowledge, as far as we know, this is the first description of the presence of PMQR genes in *P. aeruginosa* isolates in Brazil.

In addition, only a few studies have examined the consequences of resistance to antibiotics and the impact of inappropriate therapy on the outcome of patients with MDR *P. aeruginosa* infections. Thus, this study was performed to evaluate this factor, and to identify the risk factors in patients with MDR *P. aeruginosa* infections. In addition, we also aimed to determine: (i) the presence of metallo-β-lactamases genes in carbapenem-resistant isolates; (ii) the co-occurrence of PMQR determinants and altered *gyrA* and *parC* genes in fluoroquinolone-resistant isolates; and (iii) the pattern of clonal spread of *P. aeruginosa* in the hospital environment.
Materials and Methods

Study design and data collection

Active surveillance was conducted from May 2009 to December 2012 and from April to October 2014 for the detection of patients with *P. aeruginosa* infections resistant to carbapenems and fluoroquinolones at Uberlândia University Hospital (Brazil). In total, 242 episodes of *P. aeruginosa* infections obtained from 236 patients were included in the study. From this surveillance, two case-control studies were conducted: (i) to determine the risk factors associated with MDR *P. aeruginosa* infections, and (ii) to determine the risk factors associated with antimicrobial resistance and treatment outcome in patients with *P. aeruginosa* bacteremia. In both studies, only the first episode of each infection was considered. The demographic, clinical and epidemiological data of the patients were also obtained through review of medical records, following the model of National Healthcare Safety Network (NHSN).

Definitions

According to the Centers for Disease Control and Prevention (CDC), bacteremia was defined as the presence of viable bacteria in the blood, documented by a positive blood culture result [28]. The isolates were considered to be nosocomial if the infection occurred >48 h after admission and no clinical evidence of infection on admission existed [29]. The criteria used for defining MDR phenotype was: non-susceptible to ≥1 agent in ≥3 antimicrobial categories [30]. Previous antibiotic use was considered when the patient received therapy with any antibiotic for at least 72 h over a period of 30 days prior to the microbiological infection diagnosis [31]. The antimicrobial therapy was considered to be appropriate if the initial antibiotics, which were administered within 24 h of acquisition of a blood culture sample, included at least one antibiotic that was active *in vitro* [32]. The 30-day mortality was considered as the number of deaths of patients with infections during hospitalization that occurred within 30 days of the diagnosis of infection [33], and the 5-day mortality, also known as early mortality, was considered as the number of deaths within 5 days of hospitalization [34]. Hospital stays were considered prolonged if they reached or exceeded 45 days [35]. It was considered MIC50 and MIC90 represent the concentration of antimicrobial agent (μg/mL) that inhibited 50% and 90%, respectively, of the isolates tested [36].

Clinical microbiological and antibiotic resistant profile

Microbial identification and antimicrobial susceptibility tests were performed on a VITEK II system (bioMérieux, Brazil) for the following antimicrobials: aminoglycoside (gentamicin, amikacin), carbapenems (imipenem, meropenem), cephalosporin (cefepime), fluoroquinolone (ciprofloxacin) and penicillin plus β-lactamase inhibitors (piperacillin-tazobactam). Quality-control protocols were used according to the standards of the Clinical and Laboratory Standard Institute [37, 38]. The isolates with intermediate susceptibility were considered as resistant.

The minimum inhibitory concentration (MIC) and the confirmation test of resistance to imipenem (≥8 μg/mL) were performed by the E-test method, according to the manufacturer’s guidelines (AB Biodisk, Sweden) [38]. In addition, resistance to ciprofloxacin was confirmed by broth microdilution method according to Capuano [39] with modifications, and the interpretation also were made according to CLSI [38], considering resistance to ciprofloxacin ≥4 μg/mL.

Characterization of strains harboring MBL and PMQR genes

Forty clinical *P. aeruginosa* fluoroquinolone-resistant isolates were selected, being obtained from 39 patients, with various clinical infections (urinary infection, pneumonia, wound infection, otitis, and bloodstream infection).
DNA extraction was performed using a PureYield™ Plasmid Miniprep System (Promega, Brazil). Amplification of the MBL and PMQR markers (blaIMP, blaVIM, blaSPM, blaGIM, blaSIM, qnrA, qnrB, qnrC, qnrD, qnrS, qepA and aac(6')-Ib-cr) were performed using primers listed in S1 Table (available in the Supporting Information). The reaction mixture (25 μL) contained 1.0 μL DNA template (10 ng), 12.5 μL GoTaq® Green Master Mix (Promega) and 0.5 μL of each primer. Amplifications were performed in Mastercycler Personal (Eppendorf) using the following program: initial denaturation at 95°C for 2 min followed by 30 cycles of 30 seconds at 95°C, 1 min at annealing temperature (54°C for blaIMP, blaVIM, blaSPM, blaGIM and blaSIM; 51°C for qnrA, qnrB, qnrC, qnrS and qnrD; 52°C for qepA and aac(6')-Ib-cr), 1 min at 72°C and a final extension step of 5 min at 72°C. Multiplex PCR was performed for genotypic characterization of different MBL (blaIMP, blaVIM, blaSPM, blaGIM and blaSIM) and PMQR (qnrA, qnrB, qnrC, and qnrS) genes; and, for the others genes individual PCRs were carried out (qnrD, qepA and aac(6')-Ib-cr). The amplified PCR products were visualized by electrophoresis in 1.5% agarose gel by the photo documentation System L-Pix EX (Loccus Biotechnology, Brazil).

Sequencing of PMQR genes and QRDRs mutations

The PCR products of target regions for QRDR mutations (gyrA and parC) and PMQR genes (qnrS and aac(6')-Ib) were sequenced (primers listed in S1 Table), using an automatic sequencer ABI-PRISM 3100 Genetic Analyzer (Applied Biosystems, USA). Sequences were edited using SeqMan Pro alignment was carried out with MegaAlign, both of Lasergene package version 10 (DNAStar, USA) and deposited at GenBank (http://www.ncbi.nlm.nih.gov/genbank/) [accessions numbers: KT962252 (qnrS1), KT987419 (aac(6')-Ib-cr) and KT987420 (aac(6')-Ib7)].

Pulsed-Field Gel Electrophoresis (PFGE)

Isolates were typed according to the protocols described by Galetti [40] with modifications, following digestion of genomic DNA with SpeI restriction enzyme (Promega). DNA fragments were separated on 1% (w/v) agarose gels in 0.5x TBE [Tris–borate–ethylene diamine tetra-acetic acid (EDTA)] buffer using a CHEF DRIII apparatus (Bio-Rad, USA) with 6 V/cm, pulsed from 5 s to 40 s, for 21 h at 12°C. Gels were stained with ethidium bromide and photographed under ultraviolet light. Computer-assisted analysis was performed using BioNumerics 5.01 software (Applied Maths, Belgium). Comparison of the banding patterns was accomplished by the unweighted pair-group method with arithmetic averages (UPGMA) using the Dice similarity coefficient.

Statistical analysis

The Chi-square or Fisher’s exact test was used to compare discrete variables. The comparison of two quantitative variables was made using the Mann–Whitney test for nonparametric variables and the Student t test for parametric variables. Two-sided tests were used for all analyses. Multivariate analysis was performed using multiple logistic regression and the values were included when significance was <0.05 in univariate analysis. To determine inappropriate therapy for mortality within 30 days of hospitalization, a multiple logistic regression model was used to control for the effects of confounding variables. All p-value <0.05 was considered statistically significant. The epidemiological data were analyzed through the programs Graph Pad Prism® 5.0 (La Jolla, USA) and BioEstat 5.0 (Tefé, Brazil).

Ethical considerations

The data and the samples analyzed in the present study were obtained in accordance with the norms and approved by the Federal University of Uberlandia Ethics Committee (UFU),
through license number 36601814.7.0000.5152. For this study, samples were collected at the Microbiology Laboratory of the Clinical Hospital, with no contact to the patient and with the permission of the Hospital. Moreover, this study was retrospective and there are no patient identification when performed data collection, so the ethics committee dismissed the informed consent term and clarified.

**Results**

From May 2009 to December 2012 and from April to October 2014, a total of 236 non-repetitive patients with *P. aeruginosa* infections at the University Hospital were included in the study. The univariate analysis and independent risk factors associated with MDR *P. aeruginosa* infections are summarized in Table 1. According to antimicrobial susceptibility testing results,

| Risk factor/ characteristics                  | Total n = 236 (%) | MDR n = 96 (%) | non-MDR n = 140 (%) | Univariate OR (95% CI) | P value | Multivariate OR (95% CI) | P value |
|-----------------------------------------------|-------------------|----------------|---------------------|------------------------|---------|--------------------------|---------|
| **Age [mean]; ±SD**                           | 52.7; ±22.9       | 56.5; ±18.3    | 50.6; ±25.1         | -                      | 0.211   | -                        | -       |
| **Male**                                      | 166 (70.3)        | 65 (67.7)      | 101 (72.1)          | 0.81 (0.46–1.42)       | 0.463   | -                        | -       |
| **Female**                                    | 70 (29.7)         | 31 (32.3)      | 39 (27.8)           | 1.23 (0.70–2.17)       | 0.463   | -                        | -       |
| **Length of hospital stay days [mean]; ±SD**  | 55.0; ±69.7       | 54.7; ±46.5    | 53.3; ±80.9         | -                      | 0.0669  | -                        | -       |
| **Invasive procedures**                       | 210 (88.9)        | 86 (89.6)      | 123 (87.9)          | 1.19 (0.52–2.72)       | 0.682   | -                        | -       |
| **Mechanical ventilation**                    | 126 (53.4)        | 58 (60.4)      | 68 (48.6)           | 1.62 (0.95–2.74)       | 0.073   | -                        | -       |
| **Tracheostomy**                              | 120 (50.6)        | 56 (58.3)      | 64 (45.7)           | 1.66 (0.98–2.81)       | 0.056   | -                        | -       |
| **Urinary catheter**                          | 163 (69.1)        | 71 (73.9)      | 92 (65.7)           | 1.48 (0.83–2.63)       | 0.178   | -                        | -       |
| **Central venous catheter**                   | 192 (81.4)        | 77 (80.2)      | 115 (82.1)          | 0.88 (0.45–1.71)       | 0.707   | -                        | -       |
| **Surgical drain**                            | 41 (17.4)         | 17 (17.7)      | 24 (17.1)           | 1.04 (0.52–2.06)       | 0.910   | -                        | -       |
| **Enteral probes/gastric nutrition**          | 172 (72.9)        | 71 (73.9)      | 101 (72.1)          | 1.10 (0.61–1.97)       | 0.758   | -                        | -       |
| **Haemodialysis**                             | 71 (30.1)         | 29 (30.2)      | 42 (30.0)           | 1.01 (0.57–1.78)       | 0.927   | -                        | -       |
| **Co-morbidity conditions**                   | 146 (61.9)        | 57 (59.4)      | 89 (63.6)           | 0.84 (0.49–1.43)       | 0.514   | -                        | -       |
| **Heart failure**                             | 60 (25.4)         | 27 (28.1)      | 33 (23.6)           | 1.27 (0.70–2.29)       | 0.430   | -                        | -       |
| **Neoplasia**                                 | 36 (15.2)         | 9 (9.4)        | 27 (19.3)           | 0.43 (0.19–0.97)       | 0.037   | -                        | -       |
| **Diabetes mellitus**                         | 40 (16.9)         | 22 (22.9)      | 18 (12.9)           | 2.01 (1.01–4.00)       | 0.043   | -                        | -       |
| **Chronic renal failure**                     | 66 (28.0)         | 28 (29.2)      | 38 (27.1)           | 1.10 (0.62–1.97)       | 0.733   | -                        | -       |
| **Previous use of antimicrobial**             | 195 (82.6)        | 82 (85.4)      | 113 (80.7)          | 1.40 (0.69–2.83)       | 0.349   | -                        | -       |
| **Carbapenem**                                | 119 (50.4)        | 56 (58.3)      | 63 (45.0)           | 1.71 (1.01–2.89)       | 0.044   | 0.8928 (0.51–1.55)       | 0.687   |
| **Fluoroquinolone**                           | 51 (21.6)         | 24 (25.0)      | 27 (19.3)           | 1.41 (0.76–2.64)       | 0.275   | -                        | -       |
| **Cephalosporin (3 and 4th generation)**      | 161 (68.2)        | 65 (67.7)      | 96 (68.6)           | 0.96 (0.55–1.68)       | 0.888   | -                        | -       |
| **Inappropriate therapy**                     | 85 (36.0)         | 49 (51.0)      | 36 (25.7)           | 3.01 (1.73–5.23)       | <0.0001 | 3.0169 (1.72–5.31)       | 0.0001  |

1 Multidrug-resistant;  
2 Odds ratio;  
3 Confidence interval;  
4 Standard deviation.  
*P ≤ 0.05 —statistically significant for risk factor.

Table 1. Univariate and multivariate analyses, mortality and independent risk factors associated with multidrug-resistant *P. aeruginosa* infections.

*PLOS ONE* | DOI:10.1371/journal.pone.0155914 May 24, 2016 5 / 15
MDR *P. aeruginosa* infections occurred in 40.7% of the cases. Data from these patients (MDR) were compared with a sensitive *P. aeruginosa* infections group (non-MDR). In the whole series, prior exposure to carbapenems and inappropriate therapy as well as the co-morbidity condition (diabetes mellitus) were significant in the univariate analysis by MDR *P. aeruginosa* infections. The results of multivariate analyses showed that factors independently associated with MDR *P. aeruginosa* were patients who received inappropriate therapy. The Kaplan–Meier cumulative survival estimates (Fig 1) for patients with inappropriate versus appropriate therapy showed that the first group had a lower probability of survival than the group that received appropriate therapy (*P* = 0.0047). The 30-day mortality rate of the first group was 55.3%, whereas that of the second group was 34.4%. Furthermore, of the total mortality, 5-day mortality rate was 40.6% (54/133) independently of the therapy received.

Antimicrobial therapy and clinical outcome of patients with or without bacteremia caused by *P. aeruginosa* were evaluated and it can be observed that patients with bacteremia caused by isolates resistant to carbapenems, had a high 5-day mortality rate. Moreover, the time of hospital stay was significantly higher for the MDR and fluoroquinolone-resistant groups when compared with susceptible group, and the latter was also independently associated in the multivariate analyses (Table 2).

The antimicrobial resistance analysis of the 242 *P. aeruginosa* isolates is presented in Table 3. The resistance to carbapenem and fluoroquinolones were the most frequents, 45.9% and 42.6% respectively, followed by resistance to aminoglycosides (38.4%), cephalosporin (3rd and 4th generation) (34.3%) and piperacillin/tazobactam (24.8%). No isolate was resistant to polymyxin.

Table 4 summarizes the characterization of forty *P. aeruginosa* isolates that were resistant to fluoroquinolones (100%) and/or resistant to carbapenems (80%), with 87.5% (35/40) of nosocomial origin and 12.5% (5/40) classified as community acquired. The isolates were recovered from clinical specimens as blood (52.5%; 21/40), tracheal secretion (20.0%; 8/40), urine (15.0%; 6/40), tissue fragment (10.0%; 4/40) and otitis (2.5%; 1/40). All patients with bloodstream infection used a central venous catheter, and 50% of patients with urinary infection had a urinary catheter. Furthermore, 86.7% (13/15) of the patients with pneumonia had ventilator-associated pneumonia (VAP). Antimicrobial susceptibility results were analyzed and 87.5% (35/40)
isolates was characterized as MDR. The resistance rates to carbapenem, cefepime, piperacillin/tazobactam, and aminoglycoside were 80% (32/40), 72.5% (29/40), 57.5% (23/40) and 55% (22/40), respectively (data not shown). Moreover, 40% community isolates were characterized as MDR. The minimum inhibitory concentrations of imipenem and ciprofloxacin to inhibit 90% of $P. aeruginosa$ isolates selected were $32$ and $64 \mu g/mL$, respectively.

Multiplex PCR to MBL was conducted only for carbapenem-resistant $P. aeruginosa$ (32/40) from nosocomial and community infections, with 85.7% (30/35) and 40.0% (2/5), respectively, and seven isolates showed amplifications consistent with MBL genes indentified as $\text{bla}^{\text{SPM-1}}$ and $\text{bla}^{\text{VIM}}$ types.

The frequency of isolates that presented PMQR genes ($\text{qnrS}_1$ and $\text{aac}(6')-\text{Ib-cr}$) was 5.3% (2/38). The only MDR isolate of nosocomial origin that presented the $\text{qnrS}_1$ gene was recovered from lung, with the following MIC for ciprofloxacin and imipenem, 64 $\mu g/mL$ and $\geq 32$ $\mu g/mL$, respectively. This isolate did not show to present the MBL genes tested ($\text{bla}^{\text{IMP}}, \text{bla}^{\text{VIM}}, \text{bla}^{\text{SPM}}, \text{bla}^{\text{GIM}}$ and $\text{bla}^{\text{SIM}}$). Overall, 85% (34/40) of the isolates harboured $\text{aac}(6')-\text{Ib}$ gene, and was recovered from blood (38.2%; 13/34), tracheal aspirate (32.4%; 11/34), urine (17.6%; 6/34) and tissue fragment (11.8%; 4/34). The sequencing results showed that only one nosocomial isolate, recovered from tissue fragment and showed non-MDR profile, presented the cr variant ($\text{aac}(6')-\text{Ib-cr}$ gene), with a MIC of 64 $\mu g/mL$ for ciprofloxacin. Besides that, 87.5% (28/32)

Table 2. Antimicrobial therapy and clinical outcome of patients with bacteremia caused by $P. aeruginosa$ resistant to carbapenems, fluoroquinolones and multiresistant.

| Patients with bacteremia | Patients without bacteremia | Univariate |
|--------------------------|-----------------------------|------------|
|                          | $n = 158$ (%)               | $n = 78$ (%)| $P$ value | OR$^1$ (CI$^2$ 95%) |
| **Carbapenem resistant isolates**$^3$ |                       |            |           |                      |
| Total                    | 70 (100.0)                  | 39 (100.0)  | -         | -                    |
| 5-day mortality          | 22 (31.4)                   | 5 (12.8)    | 0.0310$^*$| 3.117 (1.073–9.051)  |
| 30-day mortality         | 36 (51.4)                   | 14 (35.9)   | 0.1188    | 1.891 (0.8453–4.229) |
| Inappropriate therapy    | 32 (45.7)                   | 24 (61.5)   | 0.1131    | 0.5263 (0.2368–1.170) |
| Prolonged hospital stay$^6$| 40 (57.1)                   | 15 (38.5)   | 0.0615    | 2.133 (0.9582–4.749) |
| **Fluoroquinolone resistant isolates**$^4$ |                       |            |           |                      |
| Total                    | 67 (100.0)                  | 31 (100.0)  | -         | -                    |
| 5-day mortality          | 21 (31.3)                   | 4 (12.9)    | 0.0796    | 3.082 (0.9561–9.932) |
| 30-day mortality         | 33 (49.2)                   | 9 (29.0)    | 0.0600    | 2.373 (0.9534–5.904) |
| Inappropriate therapy    | 30 (44.8)                   | 21 (67.7)   | 0.0343    | 0.3861 (0.1579–0.9440) |
| Prolonged hospital stay$^6$| 38 (56.7)                   | 7 (22.6)    | 0.0016$^*$| 4.493 (1.701–11.86)  |
| **Multidrug-resistant isolates** |                       |            |           |                      |
| Total                    | 67 (100.0)                  | 29 (100.0)  | -         | -                    |
| 5-day mortality          | 21 (31.3)                   | 4 (13.8)    | 0.0820    | 2.853 (0.8809–9.241) |
| 30-day mortality         | 32 (47.8)                   | 11 (37.9)   | 0.3738    | 1.496 (0.6141–3.645) |
| Inappropriate therapy    | 30 (44.8)                   | 19 (65.5)   | 0.0620    | 0.4267 (0.1727–1.055) |
| Prolonged hospital stay$^6$| 39 (58.2)                   | 7 (24.1)    | 0.0022$^*$| 4.378 (1.644–11.66)  |

$^1$Odds ratio;
$^2$Confidence interval;
$^3$Imipenem and/or meropenem;
$^4$Ciprofloxacin and/or norfloxacain;
$^5$Length of stay $\geq$ 45 days;
$^6$Significant risk factor by multivariate analyses $P = 0.0088$, OR $= 3.8151$ (CI $= 1.40–10.38$); $^*P \leq 0.05$ –statistically significant.

DOI:10.1371/journal.pone.0155914.t002
harboured the \textit{aac(6')-Ib\_7} variant. None of the isolates harboured \textit{qnrA}, \textit{qnrB}, \textit{qnrC}, \textit{qnrD}, and \textit{qepA} genes. Moreover, among PMQR-positive isolates none had community origin.

Of the 20 \textit{P. aeruginosa} isolates evaluated for QRDR mutations in \textit{gyrA} and \textit{parC} (Thr83Ile; Ser87Leu; Glu91Lys), none presented concomitant PMQR determinants (Table 4).

A total of 17 PFGE patterns (A-Q) of \textit{P. aeruginosa} were observed among the 21 isolates analyzed, comprising 3 main clones: A (14.3%; 3/21), B (9.5%; 2/21), C (9.5%; 2/21) (Table 4 and Fig 2). The pulsotype A had two subtypes (A and A1), and they belonged to isolates that contained the \textit{bla}_{\text{SPM}} gene, while B and C had only one.

**Discussion**

Recent studies have shown that multi-drug resistance and several virulence determinants are key factors that contribute to the global spread of \textit{P. aeruginosa} in hospitals [41–43]. The present study evaluated the risk factors for the development of infections caused by MDR \textit{P. aeruginosa}, as well as those associated with antimicrobial resistance and treatment outcome in patients with bacteremia. The independent risk factors for development of MDR \textit{P. aeruginosa} infections include prior use of antibiotics (carbapenems, fluoroquinolones, broad-spectrum cephalosporins, and aminoglycosides), being bedridden or in the intensive care unit, prolonged hospital stay, \textit{P. aeruginosa} infection or colonization within a previous period of one year, malignant disease, mechanical ventilation, and history of chronic obstructive pulmonary disease [44, 45]. Data of univariate analysis from this study have corroborated some of these risk factors. However, only inappropriate therapy was a risk predictor independent associated for developing MDR \textit{P. aeruginosa} infections, but it must be considered as such within the epidemiological context [46]. Some studies provide evidences of a general view that the development of MDR can be caused by treatment that is inappropriate, incorrect and widespread use of carbapenems [3, 46]. The pressure of carbapenems use has contributed to an explosive increase of KPC (carbapenemase-producing \textit{K. pneumoniae}), which has been responsible for 70.9% of \textit{K. pneumoniae} infections in the hospital of this study (data not shown).

Among patients with bacteremia (158 patients), 44.3% had isolates resistant to carbapenems, 42.4% resistant to fluoroquinolones and 42.4% with a multidrug-resistant profile. The association of bacteremia with antimicrobial resistant isolates is common, but few studies have addressed this problem systematically [47–49]. In hospitalized patients, the association between bacteremia and fluoroquinolone-resistant \textit{P. aeruginosa} was observed in our study with a high frequency of patients remained hospitalized longer (56.7%), independently associated with bacteremia. Similar frequencies were also observed for those patients with MDR isolates (58.2%). In the carbapenem-resistant group, was observed a higher early mortality rate (5 days) that was statistically significant with those that had bacteremia infections. These aspects

| Antimicrobials         | Resistant | Sensitive |
|------------------------|-----------|-----------|
|                        | Isolates  | Rate (%)  | Isolates  | Rate (%)  |
| Cephalosporin (3rd and 4th generation) | 83        | 34.3      | 159      | 65.7      |
| Carbapenem             | 111       | 45.9      | 131      | 54.1      |
| Aminoglycoside         | 93        | 38.4      | 149      | 61.6      |
| Polymyxin              | 0         | 0         | 242      | 100.0     |
| Piperacillin/Tazobactam| 60        | 24.8      | 182      | 75.2      |
| Fluoroquinolone        | 103       | 42.6      | 139      | 57.4      |

doi:10.1371/journal.pone.0155914.t003
have often been observed in developing countries like Brazil [48, 50, 51], where the macro and micro-regional differences in relation to the hospitals are extremely significant, as well as the characteristics of the hospitalized population [29, 52]. Besides, the lack of the microbiology laboratories and human and financial resources, a result of poor implementation of control practices for prevention of nosocomial infections, favors the intra and inter-hospital transmission of resistant pathogens that exhibit adaptation to the environment [6, 52]. Another aspect that must be considered is that the antimicrobial use is commonly abusive, empirical and often less judicious [6, 52]. A study performed by Dantas [53] in the same university hospital of this

| Characteristics                                      | Positive/analyzed (%) |
|------------------------------------------------------|-----------------------|
| **Phenotype**                                        |                       |
| Multiresistant                                       | 35/40 (87.5)          |
| Non-multiresistant                                   | 05/40 (12.5)          |
| **Metallo-β-lactamase**                              |                       |
| SPM                                                  | 05/32 (15.6)          |
| VIM                                                  | 02/32 (06.2)          |
| **PMQR/aac(6’)-Ib**                                 |                       |
| qnrS₁                                                 | 01/38 (02.6)          |
| aac(6’)-Ib-cr                                        | 01/38 (02.6)          |
| aac(6’)-Ib₇                                         | 28/32 (02.6)          |
| **QRDR² mutations**                                 |                       |
| gyrA: Thr83Ile                                       | 20/20 (100.0)         |
| parC: Ser87Leu                                       | 16/20 (80.0)          |
| parC: Glu91Lys                                        | 01/20 (05.0)          |
| gyrA + parC: Thr83Ile + Ser87Leu                     | 16/20 (80.0)          |
| gyrA + parC: Thr83Ile + Glu91Lys                      | 01/20 (05.0)          |
| **PFGE³ patterns**                                   |                       |
| A                                                     | 03/21 (14.3)          |
| B                                                     | 02/21 (09.5)          |
| C                                                     | 02/21 (09.5)          |
| D-Q⁴                                                  | 01/21 (04.8)          |
| **Predominant clones**                               |                       |
| A, B and C                                            | 07/21 (33.3)          |
| **Antimicrobial**                                    | MIC⁵ (µg/mL)          |
| Imipenem                                             |                       |
| MIC₅₀                                                 | ≥32                   |
| MIC₉₀                                                 | ≥32                   |
| Ciprofloxacin                                         |                       |
| MIC₅₀                                                 | 16                    |
| MIC₉₀                                                 | 64                    |

¹Plasmid-mediated quinolone resistance or aminoglycoside 6’-N-acetyltransferase type Ib;  
²Quinolone-resistance determining region;  
³Pulsed field gel electrophoresis;  
⁴each clone;  
⁵Minimum inhibitory concentration (n = 38). Of the total isolates, 12.5% are of Community origin (5/40).  

1Plasmid-mediated quinolone resistance or aminoglycoside 6’-N-acetyltransferase type Ib;  
2Quinolone-resistance determining region;  
3Pulsed field gel electrophoresis;  
4each clone;  
5Minimum inhibitory concentration (n = 38). Of the total isolates, 12.5% are of Community origin (5/40).  

doi:10.1371/journal.pone.0155914.004
study, showed that the density of antibiotic use was much higher when compared with hospitals with similar size in other countries, allowing MDR strains such as Gram-negative non-fermentative bacteria to emerge and spread quickly [54].

In addition to the multi-drug resistance, special attention was given in this study to P. aeruginosa resistant to carbapenems, considering the significant increase of this resistance in Latin America and widespread of different clones associated with the production enzymes of the MBL type [55–58]. The predominant MBL-encoding gene in Brazil is blaSPM-1, which has been disseminated by the MDR P. aeruginosa clone SP/ST277, considered a high-risk clone [7, 18, 59, 60]. The blaSPM-1 gene was first detected in São Paulo, and later in others cities in Brazil, moreover several studies have shown its global spread and pandemic potential, causing important morbidity and mortality in hospital infections [18, 43, 60, 61]. In our study, we observed a high frequency of SPM among the isolates, especially those belonging to clone A. In addition, two isolates harboring blaVIM were detected. An increase in the rates of P. aeruginosa isolates containing the gene blaVIM has been also observed in others hospitals in Brazil [62, 63]. The frequent data among different types of metallo-β-lactamase in Brazil, and not in other

Fig 2. UPGMA dendrogram of PFGE profiles of 21 clinical P. aeruginosa isolates used in this study using the Dice coefficient under 1% tolerance and 1% optimization. A similarity coefficient of 80% was chosen for cluster definition. 1Plasmid-mediated quinolone resistance determinants or aminoglycoside 6’-N-acetyltransferase type Ib; 2Metallo-β-lactamase; 3negative; 4not tested.

doi:10.1371/journal.pone.0155914.g002
countries, especially those developed, suggest the spread of specific clones and the knowledge of these facts may contribute to improving the multidrug resistance scenario.

Besides the carbapenem resistance, resistance to fluoroquinolones has become an increasing problem, so far, only a few studies have investigated the occurrence of PMQR in *P. aeruginosa* [27, 29, 64, 65]. PMQR is an important phenomenon that is being disseminated worldwide and the most relevant PMQR genes to date are the *aac(6\'-Ib-cr, qnr* and genes encoding efflux pumps such as *qepA* [24]. Surprisingly, the results from this study demonstrated for the first time the presence of PMQR genes in clinical isolates of *P. aeruginosa* in Brazil (5.3%), as well as a very significant high frequency not shown in other studies of the *aac(6\')-Ib* variant. The PMQR rate in our study was higher than that some reported in the literature [27, 65]. According to the study reported by Jiang et al. [27], the frequency of clinical isolates carrying the *aac(6\')-Ib-cr* gene was 1.9% (2/106 isolates), and the total rate of PMQR determinants was 3.8% among *P. aeruginosa* isolates, while in the Yang and colleagues [65] study, only one in 256 *P. aeruginosa* isolates (0.4%) showed a PMQR gene. The higher detection frequency of these genes in our study reflects most likely the complexity of epidemiology and resistance mechanisms associated with *P. aeruginosa* in developing countries. The co-existence of different PMQR genes in the same clinical isolate was not observed throughout this study, although it has been reported by Jiang et al. [27].

Regarding the target site mutations in QRDR of fluoroquinolone resistant *P. aeruginosa*, we observed mutations consistent with those published previously in all isolates tested [66–68]. Of total, 20 *Pseudomonas aeruginosa* of nosocomial origin were evaluated for mutations in *gyrA* and *parC*, and none of them presented PMQR genes. However, according to literature evidences, the chromosomal QRDR mutations in *gyrA* and *parC* genes are crucial to fluoroquinolone resistance, and their association with PMQR determinants may have an additional role that contributes to resistance to fluoroquinolones [26].

Another interesting observation from this study was the identification of a mixed wound infection by *P. aeruginosa* and *E. coli* in the patient who presented *P. aeruginosa* harboring the PMQR gene *aac(6\')-Ib-cr*. In a previous evaluation of *E. coli* infections in the same hospital, 71.4% had *aac(6\')-Ib-cr* gene (data not shown). The epidemiology of *P. aeruginosa* in this hospital proved to be complex and can be explained by its involvement in the propagation through transference of plasmids to different species as well as by clonal spread.

PFGE results, in this study, suggested that *P. aeruginosa* isolates harboring PMQR genes or mutations in *gyrA* and *parC* were not closely related, except in those containing SPM clone, wherein in the literature showing results with a similarity clonal among isolates of MDR *P. aeruginosa* [69].

In conclusion, our results confirm previous findings regarding the dissemination of SPM-type clones in Brazil, and contribute whit additional evidence that may indicate that inappropriate therapy may be a crucial factor to the emergence of MDR isolates, besides being related to worse prognosis. Additionally, this study demonstrates for the first time in Brazil the presence of the PMQR determinants in *P. aeruginosa*, spreading in the hospital. Future follow-up surveillance studies of molecular epidemiology in Brazilian hospitals have crucial importance to infection-control practices and reduce the effects of these infections on hospital patients.

### Supporting Information

**S1 Table.** Primer nucleotide sequences and amplicon sizes of the PCR carried out for the detection and/or sequencing of antimicrobial resistance genes in this study.

(DOC)
Acknowledgments

The authors wish to thank Silvia Dias Oliveira (Immunology and Microbiology Laboratory, Faculty of Biosciences Pontifical, Catholic University of Rio Grande do Sul), Márcia Maria Camargo Morais (Microbial Resistance Laboratory, University of Pernambuco) and Magna Cristina de Paiva (Federal University of São João del Rei, Dona Lindu Campus, Divinópolis), who kindly provided the control strains to this study. We thank Daise Aparecida Rossi (Applied Animal Biotechnology Laboratory of the Faculty of Veterinary Medicine) for the technical support. We also thank FAPEMIG (Fundação de Amparo à Pesquisa de Minas Gerais) and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) for the financial support and scholarships.

Author Contributions

Conceived and designed the experiments: BFA PPGF RMR. Performed the experiments: BFA MLF PADC SR RCCD IRG ALSF CSDB DWDFB RMR PPGF JY. Analyzed the data: BFA MLF PADC SR RCCD IRG ALSF CSDB DWDFB RMR PPGF JY. Contributed reagents/materials/analysis tools: RMR PPGF JY. Wrote the paper: BFA RMR PPGF JY.

References

1. Zavascki AO, Gaspareto PB, Martins AF, Gonçalves AL, Barth AL. Outbreak of carbapenem-resistant *Pseudomonas aeruginosa* producing SPM-1 metallo-ß-lactamase in a teaching hospital in southern Brazil. The Journal of Antimicrobial Chemotherapy 2005; 56: 1148–1151. PMID:16239284
2. Xavier DE, Picaco RC, Girardello R, Fehlberg LCC, Gales AA. Efflux pumps expression and its association with porin down-regulation and ß-lactamase production among *Pseudomonas aeruginosa* causing bloodstream infections in Brazil. BMC Microbiol. 2010; 10: 1–7.
3. Moreira MR, Guimarães MP, Rodrigues AAA, Gontijo-Filho PP. Antimicrobial use, incidence, etiology and resistance patterns in bacteria causing ventilator-associated pneumonia in a clinical-surgical intensive care unit. Revista da Sociedade Brasileira de Medicina Tropical 2013; 46: 39–44. PMID: 23563823
4. Porto JP, Santos RO, Gontijo-Filho PP, Ribas RM. Active surveillance to determine the impact of methicillin resistance on mortality in patients with bacteremia and influences of the use of antibiotics on the development of MRSA infection. Revista da Sociedade Brasileira de Medicina Tropical 2013; 46: 713–718. doi:10.1590/0037-8682-0199-2013 PMID: 24474012
5. Borges LFA, Rocha LA, Nunes MJ, Gontijo Filho PP. Low Compliance to Handwashing Program and High Nosocomial Infection in a Brazilian Hospital. Hindawi Publishing Corporation Interdisciplinary Perspectives on Infectious Diseases 2012: 579–681. doi: 10.1155/2012/579681
6. Padoveze MC, Fortaleza CMCB, Kiffer C, Barth AL, Carneiro ICRS, Giamberardino HIG et al. Structure for prevention of health care–associated infections in Brazilian hospitals: A countrywide study. Am J Infect Control. 2015: 1–6. doi: 10.1016/j.ajic.2015.08.004
7. Gales AC, Menezes LC, Silbert S et al. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant *Pseudomonas aeruginosa* producing SPM metallo-ß-lactamase. J Antimicrob Chemother. 2003; 52: 699–702. PMID: 12951331
8. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among gram-negative bacilli isolated from Latin America: results from SENTRY antimicrobial Surveillance Program (Latin America, 2008–2010). Diagnostic Microbiology and Infections Diseases 2012; 73: 354–360.
9. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC and oprD expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates. Antimicrobial Agents and Chemotherapy 2006; 50: 1633–1641. PMID: 16641429
10. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clinical Microbiology Reviews 2007; 20: 440–458. PMID: 17630394
11. Gülmez D et al. Carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. International Journal of Antimicrobial Agent. 2008; 31: 523–6.
12. Gootz TD et al. Genetic organization of transposase regions surrounding bla*KPC* carbapenemase genes on plasmids from *Klebsiella* strains isolated in a New York City hospital. Antimicrobial Agents and Chemotherapy 2009; 53: 1998–2004. doi: 10.1128/AAC.01355-08 PMID: 19258268
13. Cezário RC, Morais LD, Ferreira JC, Costa-Pinto RM, Darini ALC, Gontijo-Filho PP. Nosocomial outbreak by imipenem-resistant metallo-β-lactamase-producing *Pseudomonas aeruginosa* in an adult intensive care unit in a Brazilian teaching hospital. Enfermedades Infecciosas y Microbiología Clínica 2009; 27: 269–274. doi: 10.1016/j.eimc.2008.09.009 PMID: 19386392

14. Scheffer MC, Bazzo ML, Steindel M, Darini AL, Clímaco E, Dalla-Costa LM. Intrahospital spread of carbapenem-resistant *Pseudomonas aeruginosa* in a University Hospital in Florianópolis, Santa Catarina, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 2010; 43: 367–371. PMID: 20802932

15. Samuelsen O, Toleman MA, Sundsfjord A, Rydberg J, Leegaard TM, Walder M et al. Molecular epidemiology of metallo-beta-lactamase-producing *Pseudomonas aeruginosa* isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrobial Agents and Chemotherapy 2010; 54: 346–352. doi: 10.1128/AAC.00824-09 PMID: 19884381

16. Bennett PM. Integrons and gene cassettes: a genetic construction kit for bacteria. Antimicrob. Agents Chemother. 1999; 43: 1–4.

17. King D, Strynadka N. Crystal structure of New Delhi metallo-β-lactamase reveals molecular basis for antibiotic resistance. Published by Wiley-Blackwell. VC 2011 The Protein Society. Protein Science 2011; 20: 1484–1491.

18. Fonseca EL, Marin MA, Encinas F, Vicente ACP. Full characterization of the integrative and conjugative element carrying the metallo-β-lactamase bla*SPM-1* and bicyclomycin bcr1 resistance genes found in the pandemic *Pseudomonas aeruginosa* clone SP/ST277. *J Antimicrob Chemother*. 2015; 10. 1093/jac/dkv152

19. Salabi AE, Toleman MA, Weeks J et al. First report of the metallo-blactamase SPM-1 in Europe. Antimicrob Agents Chemother. 2010; 54: 582. doi: 10.1128/AAC.00719-09 PMID: 19858251

20. Fonseca EL, Freitas FS, Vicente AC. The colistin-only-sensitive Brazilian *Pseudomonas aeruginosa* clone SP (sequence type 277) is spread worldwide. Antimicrob Agents Chemother. 2010; 54: 2743. doi: 10.1128/AAC.00012-10 PMID: 20368398

21. Woodford N. Rapid Characterization of β-lactamases by Multiplex PCR. In: Gillespie SH, Mchugh TD. Antibiotic Resistance Protocols: Second Edition, Methods in Molecular Biology. 2010; 642: 181–200.

22. Andrade LN, Woodford N, Darini ALC. International gatherings and potential for global dissemination of São Paulo metallo-β-lactamase (SPM) from Brazil. International Journal of Antimicrobial Agents 2014; 43: 195–200.

23. Agnello M, Wong-Beringer A. Differentiation in Quinolone Resistance by Virulence Genotype in *Pseudomonas aeruginosa*. PLoS one 2012; 7: e42973. doi: 10.1371/journal.pone.0042973 PMID: 22905192

24. Rodríguez-Martínez JM, Cano ME, Velasco C, Martínez-Martínez L, Pascual Á. Plasmid mediated quinolone resistance: an update. *J Infect Chemother*. 2011; 17: 149–82. doi: 10.1007/s10156-010-0120-2 PMID: 20862566

25. Yang H, Chen H, Yang Q, Chen M, Wang H. High prevalence of plasmid mediated quinolone resistance genes qnr and aac(6’)-Ib-cr in clinical isolates of *Enterobacteriaceae* from nine teaching hospital in China. Antimicrob Agents Chemother. 2008; 52: 4268–73. doi: 10.1128/AAC.00830-08 PMID: 18809939

26. Piekarowska K, Wołkowicz T, Zacharczuk K, Rzeckowska M, Chrost A, Bareja E et al. Co-existence of plasmid-mediated quinolone resistance determinants and mutations in gyrA and parC among fluoroquinolone-resistant clinical *Enterobacteriaceae* isolated in a tertiary hospital in Warsaw, Poland. International Journal of Antimicrobial Agents 2015; 45: 239–246. doi: 10.1016/j.ijantimicag.2014.09.019 PMID: 25468717

27. Jiang X, Yu T, Jiang X, Zhang W, Zhang L, Ma J. Emergence of plasmid-mediated quinolone resistance genes in clinical isolates of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in Henan, China. Diagn Microbiol Infect Dis. 2014; 79: 381–386. doi: 10.1016/j.diagmicrobio.2013.03.025 PMID: 24805186

28. CDC. Guidelines for the prevention of intravascular catheter–related infections. MMWR Morb Mortal Wkly Rep. 2002; 51: 1–36.

29. Bouchillon S, Hoban DJ, Badal R, Hawser S. Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results, 2009–2010. The Open Microbiology Journal 2012; 6: 74–78.

30. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18: 268–81. doi: 10.1111/j.1469-0691.2011.03570.x PMID: 21793988
31. Guilen TA, Guner R, Celikbilek N, Keske S, Tassyaran M. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant Acinetobacter baumannii. International Journal of Infectious Diseases 2015; 38: 32–35. doi:10.1016/j.ijid.2015.06.014 PMID: 26129972

32. Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford Guide to Antimicrobial Therapy, Sperryville, VA: Antimicrobial Therapy 2007; 37.

33. Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. 2007; 51: 3510–3515. PMID: 17646415

34. Burgos J, Luján M, Larrosa MN, Pedro-Botet ML, Fontanals D, Quesada MD, Lung M, Bermudo G, Almirante B, Falcó V. The problem of early mortality in pneumococcal pneumonia: a study of risk factors. Eur Respir J. 2015. doi:10.1183/09031936.00034415 PMID: 8616285

35. Mcclaran J, Berglas RT, Franco ED. Long hospital stays and need for alternate level of care at discharge Does family make a difference for elderly patients? Canadian Family Physician 1996; 42: 449–461. PMID: 23241381

36. Schwarz S, Silley P, Simjee S, Woodford N, Duijkeren EV, Johnson AP, Gaastra W. Editorial: Assessing the antimicrobial susceptibility of bacteria obtained from animals. J Antimicrob Chemother. 2010.

37. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute. 2014.

38. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute. 2012.

39. Capuano VSC. Estudo comparativo de métodos fenotípicos e biomoleculares para determinação de resistência a antibióticos em cepas de Salmonella spp isoladas de coiro e carcaça de bovinos e produtos cárneos. Dissertação de mestrado. Universidade de São Paulo, Faculdade de Ciências Farmacêuticas. São Paulo. 2012.

40. Galetti R. Estudo de Pseudomonas aeruginosa produtoras de metalo-beta-lactamas e de genes envolvidos na resistência aos carbapenênicos. 49 f. Master Thesis—Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Ribeirão Preto, Brazil. 2010.

41. Beceiro A, Tomás M, Bou G. Antimicrobial Resistance and Virulence: a Successful or Deleterious Association in the Bacterial World?. Clinical Microbiology Reviews 2013; 26: 185–230. doi:10.1128/CMR.00059-12 PMID: 23554414

42. Koutrasgiannou M, Drougka E, Liakopoulos A, Jelastopoulu E, Petinaki E, Anastassiou ED, Spiliopoulou I, Christofidou M. Spread of Multidrug-Resistant Pseudomonas aeruginosa Clones in a University Hospital. Journal of Clinical Microbiology 2013; 51: 665–668. doi:10.1128/JCM.03071-12 PMID: 23241381

43. Galetti R, Andrade LN, Climaco EC, Pitondo-Silva A, Ferreira JC, Darini ALC. Genomic diversification and virulence features in SPM-1–producing Pseudomonas aeruginosa 13 years later. Diagnostic Microbiology and Infectious Disease 2015; 82: 179–180. doi:10.1016/j.diagmicrobio.2015.02.011 PMID: 25824724

44. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact. Antimicrobial Agents and Chemotherapy 2006; 50: 43–48. doi:10.1128/AAC.50.1.43-48.2006 PMID: 16377665

45. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 441–451. doi:10.1586/erp.10.49 PMID: 20715920

46. Van der Werf MJ, Langendam MW, Hultric E, Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J. 2012; 39: 1511–1519. doi:10.1183/09031936.00125711 PMID: 22005918

47. Groß U, Amuzu SK, Ciman R, Kassimova I, Groß L, Rabsch W, Rosenberg U, Schulze M, Stich A, Zimmermann O. Bacteremia and Antimicrobial Drug Resistance over Time, Ghana. Emerging Infectious Diseases 2011; 17: 1879–1882. doi:10.3201/eid1710.110327 PMID: 2200360

48. Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. Pseudomonas aeruginosa bacteremia: independent risk factors for mortality and impact of resistance on outcome. Journal of Medical Microbiology 2014; 63.

49. Sligl WI, Dragan T, Smith SW. Nosocomial gram-negative bacteremia in intensive care: epidemiology, antimicrobial susceptibilities and outcomes. International Journal of Infectious Diseases 2015. doi: 10.1016/j.ijid.2015.06.024
50. Conterno LO, Wey SB, Castelo A. *Staphylococcus aureus* Bacteremia: Comparison of Two Periods and a Predictive Model of Mortality. The Brazilian Journal of Infectious Diseases 2002; 6: 288–297. PMID: 12585972

51. Ferreira ML, Dantas RC, Faria ALS, Gonçalves IR, Queiroz LL, Gontijo-Filho PP, Ribas RM. Molecular epidemiological survey of the quinolone- and carbapenem-resistant genotype and its association with the type III secretion system in *Pseudomonas aeruginosa*. Journal of Medical Microbiology 2015; 64: 262–271. doi: 10.1099/jmm.0.000023 PMID: 25596115

52. Gontijo-Filho PP. Problemas da vigilância epidemiológica de infecções hospitalares sem o uso de critérios microbiológicos no Brasil. Journal of Basic and Applied Pharmaceutical Sciences 2006; 27: 97–102.

53. Dantas RC. Estudo epidemiológico molecular da resistência aos carbapenêmicos em *Pseudomonas aeruginosa* isoladas de sangue: produção de β-lactamasas, perda de porina OprD e hiperoxpressão de bombas de efluxo, PhD Thesis, Universidade Federal de Uberlândia, Uberlândia. 2015.

54. Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KJ. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother. 2011.

55. Andrade SS, Jones RN, Gales AC, Sader HS. Increasing prevalence of antimicrobial resistance among *Pseudomonas aeruginosa* isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997–2001). Journal of Antimicrobial Chemotherapy 2003; 52: 140–141. doi: 10.1093/jac/dkg270 PMID: 12775681

56. Baumgart AMK, Molinari MA, Silveira ACO. Prevalence of carbapenem-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in high complexity hospital. Braz J Infect Dis. 2010; 14: 433–436. PMID: 21221469

57. Scheffer MC, Gales AC, Barth AL, Filho JRC, Dalla-Costa LM. Carbapenem-resistant *Pseudomonas aeruginosa*–clonal spread in Southern Brazil and in the State of Goiás. Braz J Infect Dis. 2010; 14: 508–509. PMID: 21221481

58. Akya A, Salimi A, Nomanpour B, Ahmadi K. Prevalence and Clonal Dissemination of Metallo-Beta-Lactamase-Producing *Pseudomonas aeruginosa* in Kermanshah. Jundishapur J Microbiol. 2015; 8: e20980. doi: 10.5812/jmm.20980v2 PMID: 26421137

59. Wright LL, Turton JF, Livermore DM, Hopkins KL, Woodford N. Dominance of international “high-risk clones” among metallo-beta-lactamase-producing *Pseudomonas aeruginosa* in the UK. J Antimicrob Chemother. 2014; 70: 103–10. doi: 10.1093/jac/dku339 PMID: 25182064

60. Costa LMA, Fleming MECK, Paula GR, Teixeira LA, Mondino PJJ, Mondino SSB, Mendonça-Souza CRV. Production of metallo-β-lactamase among *Pseudomonas aeruginosa* strains isolated in the State of Sergipe, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 2015; 48: 212–215. doi: 10.1590/0037-8682-0198-2014 PMID: 25992939

61. Silva LV, Galdino AC, Nunes AP, Dos Santos KR, Moreira BM, Cacci LC et al. Virulence attributes in Brazilian clinical isolates of *Pseudomonas aeruginosa*. Int J Med Microbiol. 2014; 30: 990–1000.

62. Sader HS, Reis AO, Silbert S, Gales AC. IMPs, VIMs and VPMs: the diversity of metallo-β-lactamases produced by carbapenem-resistant *Pseudomonas aeruginosa* in a Brazilian hospital. Clin Microbiol Infect. 2005; 11: 73–76. PMID: 15649310

63. Franco MR, Calaffa-Filho HH, Burtattini MN, Rossi F. Metallo-β-lactamasem among imipenem-resistant *Pseudomonas aeruginosa* in a Brazilian university hospital. Clinics 2010; 65: 825–829. PMID: 21049207

64. Liu Y, Deng Q, Yu Y, Cao X, Xu Q, Wan L. Analysis of the resistance mechanism and homology of carbapenem-resistant *Pseudomonas aeruginosa*. Zhonghua Shao Shang Za Zhi 2014; 30: 15–20. PMID: 24684984

65. Yang X, Xing B, Liang C, Ye Z, Zhang Y. Prevalence and fluorquinolone resistance of *Pseudomonas aeruginosa* in a hospital of South China. Int J Clin Exp Med. 2015; 8: 1386–1390. PMID: 25785142

66. Mounemerne H, Robert J, Jarlier V, Cambau E. Type II topoisomerase mutations in ciprofloxacin-resistant strains of *Pseudomonas aeruginosa*. Antimicrob Agents Chemother. 1999; 43: 62–66. PMID: 9869566

67. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of *Pseudomonas aeruginosa*. Int J Antimicrob Agents. 2003; 21: 409–413. PMID: 12727072

68. Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of *Pseudomonas aeruginosa*. Int J Antimicrob Agents 2005; 25: 290–295. PMID: 15784307

69. Oliveira RA, Gales AC, Silva RC, Pereira MS, Filho JRC. Description and molecular characterization of metallo-β-lactamase SPM-1 in *Pseudomonas aeruginosa* clinical strains from Goiânia, Brazil. Perspectivas Médicas 2014; 25: 11–19.